INDIGO Offers Human Estrogen-related Receptor Beta Assay as a Commercial Assay for the First Time State College, PA (17 May 2022) – INDIGO Biosciences, the recognized industry leader in nuclear receptor reporter assays, announced today the expanding of their robust preclinical testing portfolio of cell-based reporter assays to include the Human Estrogen-related Receptor Beta (NR3B2;Read More
INDIGO Biosciences Inc. Announces A Record Revenue for 2021
Company Shows Another Year of Record Growth and Advancements State College, PA (23 February 2022) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, has announced a record earnings year for 2021. INDIGO showed more than a 17% percent increase in revenue vs its previous recordRead More
INDIGO Biosciences Releases New Luciferase Detection Reagent
Company Creates New Glow Type Luciferase Detection Reagent and is Offering it as an Easy-To-Use Kit State College, PA (18 January 2022) – INDIGO Biosciences, Inc. (INDIGO), a recognized industry leader in cell-based luciferase reporter assay kits and service, has developed a new luciferase detection reagent and will be offering this new reagent solely forRead More
INDIGO Biosciences Expands Portfolio for Preclinical Metabolic Disease Research
Fibroblast Growth Factor 21 Assay Targets NAFLD & Obesity State College, PA (19 October 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, after the success of their Fibroblast Growth Factor Receptor 1 and 2 (FGFR1/2) assay, has expanded their robust preclinical testing portfolio to include a new Fibroblast Growth Factor 1c/BetaRead More